Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FLTX3 is a novel multifunctional fluorescent derivative of endoxifen, the active metabolite of tamoxifen. It is synthesized by the covalent attachment of the small fluorophore nitrobenzoxadiazole (NBD) to the basic side chain of endoxifen. FLTX3 functions as a target-directed fluorescent probe for the cellular labeling of estrogen receptors (ER) in breast cancer cell lines and uterine tissues. Beyond its role as a diagnostic marker, FLTX3 exhibits an intrinsic photodynamic effect and optical gain behavior that leads to random laser (RL) emission when light is scattered within cell cultures. Research has demonstrated that FLTX3-induced RL signals can distinguish between tamoxifen-sensitive and tamoxifen-resistant MCF7 breast cancer cells, suggesting its potential as a diagnostic tool for identifying treatment resistance in metastatic ER+ breast cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FLTX3.